Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults. The study will be conducted at one site in Singapore.
Epistemonikos ID: 98203a59f0c3a90f72bebaae9a2eff6097e3263e
First added on: Mar 29, 2023